Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06388967 · ClinicalTrials.gov registry record
Pancreatic Cancer Detection Consortium
A clinical trial of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 11
- Study locations
NCT06388967 is a study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 2,000 participants, above the 386-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (418% higher). The trial reports 11 study locations across 8 states.
The verdict
NCT06388967, a study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 11
- Study locations
Study Summary
This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST PANcreatic cancer Exosome Early detectiON (PANXEON)
Study Locations (11)
Arizona
- Translational Genomics Research Institute - Phoenix
- Honorhealth - Scottsdale
California
- City of Hope Medical Center - Monrovia
- Hoag Center - Newport Beach
Other
- Nagoya University - Nagoya
- Asan Medical Center - Seoul
Illinois
- OSF HealthCare - Peoria
Louisiana
- Ochsner Medical Center - Jefferson
New Jersey
- Atlantic Health System - Morristown
South Carolina
- Piedmont Medical Center - Rock Hill
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2023-03-15 |
| Est. Completion | 2026-06-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06388967
The ClinicalTrials.gov registry entry for NCT06388967 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 386-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (418% higher). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which PANcreatic cancer Exosome Early detectiON (PANXEON) is the first listed.
NCT06388967 reports 11 study locations spanning 8 distinct geographic areas - top geographies include Arizona, California, Other.
Frequently Asked Questions
What is clinical trial NCT06388967 about?
NCT06388967 is a clinical study titled "Pancreatic Cancer Detection Consortium". This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.
What is the current status of trial NCT06388967?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2023-03-15. Estimated completion is 2026-06-18.
What conditions does trial NCT06388967 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Carcinoma.
What interventions are being tested in trial NCT06388967?
The interventions under investigation include: PANcreatic cancer Exosome Early detectiON (PANXEON) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06388967?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06388967 being conducted?
This trial has 11 study locations across Arizona, California, Illinois, Louisiana, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.